Elevated Serum Level of IL-23 Correlates with Expression of VEGF in Human Colorectal Carcinoma

Archives of Medical Research

Volumn 41, Issue 3, 2010, Pages 182-189

  Ljujic, Biljana ^a   Radosavljevic, Gordana ^a   Jovanovic, Ivan ^a   Pavlovic, Sladjana ^a   Zdravkovic, Nemanja ^a   Milovanovic, Marija ^a   Acimovic, Ljubisa ^a   Knezevic, Milan ^a   Bankovic, Dragic ^a   Zdravkovic, Dusica ^a   Arsenijevic, Nebojsa ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Colorectal carcinoma.; IL 23; P53; VEGF

Indexed keywords

INTERLEUKIN 23; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-23; MALE; MIDDLE AGED; PROGNOSIS; SERBIA; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953522676     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.02.009     Document Type: Article

References (61)

1. Colpaert C., Vermulen P., van Beest P., et al. Intratumoural hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph nodenegative breast cancer patients. Histopathology 2001, 39:416-425.
2. Fyles A., Milosevic M., Hedley D., et al. Tumour hypoxia has independent predictor impact only in patients with node negative cervix cancer. J Clin Oncol 2002, 20:680-687.
3. Rajaganeshan R., Prasad R., Guillou P.J., et al. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int J Colorectal Dis 2008, 23:1049-1055.
4. Wincewicz A., Sulkowska M., Koda M., et al. Clinicopathological significance and linkage of HIF-1 alpha and GLUT-1 distributions in human primary colorectal cancers. Pathol Oncol Res 2007, 13:15-20.
5. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000, 36:1649-1660.
6. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(suppl 3):11-16.
7. Mizukami Y., Jo W.S., Duerr E.M., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005, 11:992-997.
8. Mantovani A., Allavena P., Sica A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
9. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
10. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.
11. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
12. Langrish C.L., McKenzie B.S., Wilson N.J., et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004, 202:96-105.
13. Yen D., Cheung J., Scheerens H., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
14. Matsuki T., Nakae S., Sudo K., et al. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol 2006, 18:399-407.
15. Samoilova E.B., Horton J.L., Hilliard B., et al. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998, 161:6480-6486.
16. Fantini M.C., Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008, 95:375-380.
17. Wu S., Rhee K.J., Albesiano E., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15:1016-1022.
18. Chen Z., Laurence A., Kanno Y., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci 2006, 103:8137-8142.
19. Alkim C., Savas B., Ensari A., et al. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig Dis Sci 2009, 54:1979-1984.
20. Giatromanolaki A., Sivridis E., Maltezos E., et al. Hypoxia inducible factor 1α and 2α overexpression in inflammatory bowel disease. J Clin Pathol 2003, 56:209-213.
21. Sulkowski S., Wincewicz A., Zalewski B., et al. Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer-evaluation of the prognostic significance of these agents. Clin Chem Lab Med 2009, 47:1439-1445.
22. Pfannschmidt J., Bade S., Hoheisel J., et al. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma. Thorac Cardiovasc Surg 2009, 57:403-408.
23. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
24. Dassoulas K., Gazouli M., Rizos S., et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 2009, 486:563-569.
25. Jain L., Vargo C.A., Danesi R., et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009, 8:2496-2508.
26. Famulski W., Sulkowska M., Wincewicz A., et al. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 2006, 53:43-48.
27. Díaz R., Peña C., Silva J., et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer 2008, 123:1060-1067.
28. Baltaziak M., Koda M., Wincewicz A., et al. Relationships of p53 and Bak with EPO and EPOR in human colorectal cancer. Anticancer Res 2009, 29:4151-4156.
29. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
30. Gordon L.I., Weitzman S.A. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990, 76:655-663.
31. Christen S., Hagen T.M., Shigenaga M.K., et al. Chronic infection and inflammation lead to mutation and cancer. Microbes and Malignancy: Infection as a Cause of Cancer 1999, 35-88. Oxford University Press, New York. J. Parsonnet, S. Horning (Eds.).
32. Elson C.O., Cong Y., Weaver C.T., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132:2359-2370.
33. Kullberg M.C., Jankovic D., Feng C.G., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006, 203:2485-2494.
34. Hue S., Ahern P., Buonocore S., et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006, 203:2473-2483.
35. Uhlig H.H., McKenzie B.S., Hue S., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006, 25:309-318.
36. Zhang B., Rong G., Wei H., et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008, 26(374):533-537.
37. Stanilov N., Miteva L., Mintchev N., et al. High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis 2009, 24:151-157.
38. Schonthaler H.B., Huggenberger R., Wculek S.K., et al. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci 2009, 106:21264-21269.
39. Kortylewski M., Xin H., Kujawski M., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
40. Lovato P., Brender C., Agnholt J., et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003, 278:16777-16781.
41. Musso A., Dentelli P., Carlino A., et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005, 11:91-98.
42. Corvinus F.M., Orth C., Moriggl R., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
43. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
44. Xu Q., Briggs J., Park S., et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 25(24):5552-5560.
45. Lin J., Jin X., Rothman K., et al. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cell. Cancer Res 2002, 62:376-380.
46. Lin J., Tang H., Jin X., et al. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 2002, 21:3082-3088.
47. Niu G., Wright K.L., Ma Y., et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005, 25:7432-7440.
48. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000, 35(71):103.
49. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44.
50. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
51. Fatyol K., Szalay A.A. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J Biol Chem 2001, 276:28421-28429.
52. Zheng S., Han M.Y., Xiao Z.X., et al. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003, 9:1227-1230.
53. Hanrahan V., Currie M.J., Gunningham S.P., et al. The angiogenic switch for vascular endothelial growth factor VEGF-A, VEGF-B, VEGF-C and VEGF-D in the adenomacarcinoma sequence during colorectal cancer progression. J Pathol 2003, 200:183-194.
54. Kang S.M., Maeda K., Onoda N., et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997, 74:502-507.
55. Perrone G., Vincenzib B., Santinib D., et al. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinicopathological features in colon cancer. Cancer Lett 2004, 208:227-234.
56. Smith D.R., Goh H.S. p53 and prognosis in colorectal cancer. Ann Acad Med Singapore 1996, 25:107-112.
57. Manne U., Myers R.B., Moron C., et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997, 74:346-358.
58. Manne U., Weiss H.L., Myers R.B., et al. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer 1998, 83:2456-2467.
59. Katkoori V.R., Jia X., Shanmugam C., et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009, 15:2406-2416.
60. Gorgescu C.V., Sâftoiu A., Georgescu C.C., et al. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis 2007, 16:133-139.
61. Zhao D.P., Ding X.W., Peng J.P., et al. Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B 2005, 6:1163-1169.